---
title: "Bio-S expects a net profit attributable to the parent company of RMB 0 to 6 million in the first half of the year, a year-on-year decrease of 95.53% to 100%"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/248601885.md"
description: "According to the Zhitong Finance APP, Bio-S disclosed its performance forecast for the first half of 2025. The company expects a net profit attributable to shareholders of the listed company to be between 0 and 6 million yuan, a year-on-year decrease of 95.53%-100.00%; the net loss after deducting non-recurring gains and losses is expected to be between 9 million and 15 million yuan"
datetime: "2025-07-15T11:43:06.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/248601885.md)
  - [en](https://longbridge.com/en/news/248601885.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/248601885.md)
generator: "portal-rs"
---

# Bio-S expects a net profit attributable to the parent company of RMB 0 to 6 million in the first half of the year, a year-on-year decrease of 95.53% to 100%

According to the Zhitong Finance APP, Bio-S (301096.SZ) disclosed its performance forecast for the first half of 2025, expecting a net profit attributable to shareholders of the listed company to be between 0 and 6 million yuan, a year-on-year decrease of 95.53% to 100.00%; the net loss after deducting non-recurring gains and losses is expected to be between 9 million and 15 million yuan

### Related Stocks

- [301096.CN](https://longbridge.com/en/quote/301096.CN.md)

## Related News & Research

- [FGMA Rises to No. 38 in BD+C's 2026 Top 200 Architecture Firms Ranking](https://longbridge.com/en/news/297187912.md)
- [BIDU-SW  to Pursue Dual Primary Listing on HKEX and Nasdaq Starting Next Tue](https://longbridge.com/en/news/297102765.md)
- [Livzon MABPharm wins China approval for Lecankitug psoriasis injection](https://longbridge.com/en/news/297167246.md)
- [Subscribe for Symbiotec Pharmalab Ltd IPO; Ajcon Global](https://longbridge.com/en/news/296742246.md)
- [Haisco Enters Into Exclusive License Agreement With New US Venture Founded By Population Health Partners And ARCH Venture Partners](https://longbridge.com/en/news/296910145.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**